Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Mayo Clinic
- Study ID
- NCT06279572
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Biospecimen Collection — PROCEDUREUndergo blood sample collection
- Bone Marrow Aspirate — PROCEDUREUndergo bone marrow aspirate
- Electronic Health Record Review — OTHERMedical records are reviewed
Study Details
This study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the treatment of patients undergoing therapy of venetoclax plus azacitidine and create future immune based treatment approaches.
Key Dates
- Start date
- Apr 22, 2021
- Status verified
- Mar 2026
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 80 participants (estimated)
Arms
- Arm: Observational (blood collection, bone marrow aspirate)Patients undergo blood sample collection and bone marrow aspirate on study. Patients' medical records are reviewed.
Primary Outcome Measure
Immune profile of treatment naive acute myeloid leukemia (AML) patients receiving azacitidine plus venetoclax chemotherapy [ Time Frame: Baseline (at enrollment) ]
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | Cecilia Y. Arana Yi, M.D. (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224-9980 | Talha Badar, M.D. (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | Mithun V. Shah, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Scottsdale, AZ
By condition
By specialty
Related Studies
- Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersPHASE2 · Recruiting · Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota
- Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 MutationPHASE2 · Recruiting · City of Hope Medical Center · Duarte, California
- A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesPHASE1 · Recruiting · Orca Biosystems, Inc. · Duarte, California
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)PHASE2 · Recruiting · Fred Hutchinson Cancer Center · Tampa, Florida